A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D). (SAB-142-201(SAFEGUARD))

Principal Investigator

Dr Supriyo Basu

Contact us

Email: childrensresearch@ouh.nhs.uk

IRAS number

1013042